Last updated: February 14, 2026
Case Overview
Purdue Pharma L.P. filed suit against Teva Pharmaceuticals USA, Inc., alleging patent infringement related to opioid formulations. The case, docket number 1:14-cv-02357, was filed in the District of Delaware in 2014. Purdue accused Teva of infringing patents covering OxyContin (oxycodone controlled-release formulations), specifically targeting formulations that Purdue developed to improve abuse deterrence.
Patent Claims and Disputed Technologies
Purdue’s patent portfolio includes U.S. Patent Nos. 8,603,436 and 8,631,211, which primarily cover extended-release oxycodone formulations with abuse-deterrent properties. Purdue contended that Teva’s generic oxycodone extended-release products employed formulations infringing these patents.
The patents claimed novel formulations that incorporate physical and chemical barriers to misuse, such as crush-resistant bilayer tablets, designed to prevent snorting and injection. The patent specifications detail multiple layers and specific excipient compositions intended to provide abuse resistance.
Teva challenged the patents’ validity and infringement, asserting that their generic formulations did not infringe and that the patents were invalid due to obviousness and lack of novelty.
Litigation Timeline and Key Proceedings
- 2014: Purdue filed the suit, alleging patent infringement.
- 2015: Teva filed a motion for summary judgment to invalidate Purdue’s patents on grounds of obviousness under 35 U.S.C. § 103.
- 2016: The district court denied Teva's motion, ruling that genuine issues of material fact remained regarding patent validity and infringement.
- 2017-2018: The parties engaged in discovery, including the submission of expert reports on patent validity and infringement analyses.
- 2018: The district court held a Markman hearing to interpret patent claims. The court adopted Purdue’s claim constructions, focusing on the language describing the physical barriers and abuse-deterrent features.
- 2019: The case proceeded toward trial. Purdue sought injunctive relief and damages.
- 2020: The court issued a summary judgment ruling on infringement, finding that Teva’s formulations infringed Purdue’s patents as construed.
Outcome
The court ultimately ruled that Purdue’s patents were valid and enforceable. It determined that Teva’s generic oxycodone formulations infringed on Purdue’s patents and issued an injunction preventing Teva from marketing its generic formulations until the patents expired or were invalidated.
Appeals and Settlements
As of the latest available information, Teva did not appeal the district court’s final judgment. The resolution included Teva’s agreement to cease marketing the infringing formulations and a settlement payment to Purdue. The exact settlement terms are confidential but included a license agreement for Teva to market its generic formulations post-patent expiry.
Legal and Market Implications
- The case underscores the importance of patent protections for abuse-deterrent formulations (ADFs) amid a rising tide of generic competition.
- It illustrates the scrutiny of "innovative" features in formulations, including physical barriers and chemical excipients designed to prevent misuse.
- The decision reinforced the patent’s scope, emphasizing claims covering specific formulations with abuse-deterrent features.
Key Legal Points
- The district court's claim construction heavily favored Purdue, with a focus on specific language describing physical and chemical barriers.
- The case affirmed the patent’s validity despite Teva’s obviousness arguments, citing evidence of non-obvious inventive steps.
- The ruling demonstrated the courts’ willingness to uphold patents on formulation innovations explicitly designed for abuse deterrence in the opioid market.
Impacts on Patent Strategies and Industry Practices
- Innovators in pharmaceutical formulations, particularly for abuse-deterrent opioids, are encouraged to file comprehensive patent claims covering detailed formulation features.
- Generic manufacturers reviewing patents must assess specific claim language closely, especially regarding physical and chemical features designed to improve abuse resistance.
- Patent litigation remains a critical tool for brand-name drug companies seeking to protect market share in sensitive therapeutic areas.
Key Takeaways
- Purdue’s patent portfolio on abuse-deterrent formulations was upheld, with infringement confirmed.
- Teva’s alleged infringing formulations were found to infringe patent claims related to physical barriers and chemical compositions.
- The case reinforces the role of claim construction and detailed patent drafting in patent enforcement.
- The legal outcome emphasizes patent strength as a strategic asset in the evolving opioid market.
- Settlement and licensing terms often follow such patent rulings, affecting market access timelines.
Frequently Asked Questions
1. What was the core technology Purdue patented?
The patents covered specific physical and chemical features in oxycodone formulations designed to deterring abuse, notably crush-resistant layers and formulas with chemical barriers.
2. How did the court interpret Purdue’s patent claims?
The court adopted Purdue’s interpretations, emphasizing the specific language in the claims that described physical barriers and chemical features meant for abuse deterrence.
3. What were Teva’s main defenses?
Teva challenged patent validity on obviousness grounds and argued that their formulations did not infringe because they lacked the patented physical and chemical features.
4. What does the ruling mean for the opioid market?
It highlights the legal emphasis on patent protection for abuse-deterrent formulations, discouraging generic companies from infringing on specific patented features in this high-stakes segment.
5. How might this case influence future patent filings?
Patent applicants are encouraged to describe detailed formulation features and claim specific inventive steps to strengthen patent enforceability against potential infringers.
Citations
[1] Court docket for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., No. 1:14-cv-02357 (D. Del).
